NCZI data · Slovakia 2015 – 2025

Antidepressant use in Slovakia rose by a third in 10 years

According to data from Slovakia’s National Health Information Center (NCZI), 3.20 million packs of antidepressants were dispensed in Slovakia in 2025 — 34% more than in 2015. The estimated number of people treated with antidepressants rose from about 249,000 to 354,000, or 6.5% of the population. Almost all of the increase is accounted for by 10 substances.

Columns of capsules rising like a chart – growth in antidepressant use in Slovakia

First: this article simply summarises public data from Slovakia’s National Health Information Center (NCZI). It does not judge whether any particular treatment is appropriate — that is for your doctor to decide. If you take medication, do not change the dose without your doctor.

Key figures

+34%antidepressant packs (2.40 → 3.20 million a year)
≈ 354,000people on antidepressants in 2025 — 6.5% of the population (2015: ≈ 249,000)
3×more packs on non-reimbursed prescriptions (80,000 → 246,000)
≈ 405,000people seen by a psychiatrist — almost unchanged in 10 years

Top 10 antidepressants by growth

Almost all of the increase is accounted for by these 10 substances:

#SubstanceBrand namePacks 2015Packs 2025People 2015People 2025Change (people)
1SertralineSetaloft, Serlift250,653464,57620,300 – 26,70038,500 – 51,500+18,000 – +25,000
2VortioxetineBrintellix12,521178,0541,00013,700+12,700
3TrazodoneTrittico AC152,815267,66212,100 – 24,40021,400 – 44,200+9,400 – +19,800
4MirtazapineMirzaten177,923287,76212,600 – 14,60020,000 – 23,700+7,400 – +9,000
5VenlafaxineAlventa240,464332,48825,100 – 25,70035,700 – 38,300+10,600 – +12,700
6ParoxetineParetin, Seroxat, Arketis165,719228,29713,400 – 13,60018,500 – 18,800+5,100 – +5,200
7DuloxetineDulsevia, Duloxetin Stada, Loxentia105,653161,7208,100 – 8,50019,700 – 22,300+11,500 – +13,900
8CitalopramCitalec, Citalopram-Teva385,283427,05433,200 – 37,60034,600 – 42,300+1,400 – +4,700
9BupropionElontril, Bupropion Neuraxpharm23,30150,9931,600 – 2,9002,700 – 4,200+1,100 – +1,500
10FluoxetineMagrilan25,86749,7492,1003,800+1,700
Top 10 total1,540,1992,448,355136,000 – 150,600221,800 – 249,500+86,000 – +99,000

Numbers of people are rounded to hundreds. Range = two calculation methods (by tablet count and by WHO daily doses), see Methodology.

What the data show

  • The largest increase in people was for trazodone and sertraline. Trazodone is often prescribed at low doses for sleep; sertraline is one of the first-choice medicines for anxiety disorders, and most of its growth came after 2020.
  • Vortioxetine (Brintellix) went from a marginal medicine to around 13,700 people — the fastest market uptake of a new antidepressant.
  • Duloxetine almost tripled the number of people on treatment.
  • The number of people seen by a psychiatrist barely changed in 10 years (about 405,000), even though a third more people take antidepressants.
  • Antidepressant packs on non-reimbursed prescriptions tripled (80,000 → 246,000) and account for about 21% of the growth.
  • On the Slovak market a single brand often covers the entire use of a substance: Trittico AC, Mirzaten, Alventa, Brintellix and Magrilan.

Possible explanations — and what the data don’t show

NCZI data contain neither the diagnosis nor which doctor prescribed the medicine, so the causes of the growth cannot be determined directly. Several explanations are possible:

  • longer treatment — people may stay on medication longer than in the past, so they “accumulate” in the statistics,
  • broader use — some antidepressants are also prescribed for other problems, for example low-dose trazodone for sleep problems or duloxetine for chronic pain,
  • prescribing outside psychiatry — some medicines may also be prescribed by GPs,
  • replacing benzodiazepines — for anxiety and insomnia, part of treatment may be shifting from benzodiazepines to antidepressants; these data cannot confirm this.

Why it matters

More people on long-term treatment also means more people who will one day decide whether and how to reduce their medication gradually. Research shows that stopping abruptly can lead to withdrawal symptoms and that reduction should be gradual and supervised by a doctor.

We write more about this in How to taper off antidepressants gradually. If you are planning a gradual reduction with your doctor, see our Antidepressant tapering — gradual dose reduction service.

Methodology

The number of people is an estimate — the equivalent of people treated for a full year, calculated in two ways: (1) by the number of tablets in dispensed packs, assuming 1 tablet a day, with pack size (e.g. 28, 30 or 60 tablets) taken into account; (2) by tablet strength — total amount of active substance in mg divided by the WHO defined daily dose (DDD) and 365 days. For most substances the results almost agree. For trazodone the DDD method underestimates the number of people (the DDD is 300 mg, while 50 – 150 mg is taken for sleep). For medicines taken only part of the year, the real number of people is higher. NCZI data contain neither the diagnosis nor the prescribing doctor; the quarterly data for 2025 are preliminary.

Sources

Next step

If you have been taking medication long-term and are thinking about reducing it, the first step is a conversation with your doctor. These pages may also help: